Max Robotics — Global Service Robot Directory + US Certification

About

Marcin Miszczyk is a leading clinical researcher in urologic oncology and nuclear medicine, whose work has significantly advanced the use of PSMA PET/CT imaging in prostate cancer management. His primary research focuses on refining risk stratification and prognostic modeling for patients undergoing radical prostatectomy. Miszczyk’s most influential study, "Prognostic value of PSMA PET/CT-Based local staging in predicting biochemical recurrence after radical prostatectomy," demonstrated that PSMA PET/CT-based local staging provides superior predictive accuracy for biochemical recurrence-free survival compared to conventional imaging. This work, already garnering citations, has helped establish PSMA PET/CT as a critical tool for preoperative planning and risk assessment. Beyond this landmark paper, Miszczyk has contributed to developing integrated prognostic models that combine imaging biomarkers with clinical and pathological variables. His research directly impacts clinical decision-making by enabling more personalized treatment strategies—identifying patients at highest risk for recurrence who may benefit from adjuvant therapies. Through his rigorous methodology and focus on actionable clinical endpoints, Miszczyk has become a key figure in translating advanced molecular imaging into improved outcomes for prostate cancer patients.